Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* complicated intra-abdominal infections~Exclusion Criteria:~* infections limited to hollow viscus~* ischemic bowel disease without perforation~* acute suppurative cholangitis~* acute necrotizing pancreatitis~* pts to undergo stated abdominal repair, open abdomen technique or marsupialization~* Apache II \>25

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- NXL104/CAZ/MTZ (Type: EXPERIMENTAL): NXL104/ceftazidime + metronidazole
- Meropenem (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).